RH
Robert E. Hoffman
President, CEO and Interim CFODirector

Robert E. Hoffman insider trades: Kintara Therapeutics (KTRA) stock buys and sales

President, CEO and Interim CFO, Kintara Therapeutics Last trade Feb 15, 2022 75 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
9
Open-market trades
since 2006
14
Companies
last trade 2022

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Robert reports to the SEC

and 8 more companies

Open-market buys and sales

9 trades reported on SEC Form 4, newest first

DateStockTypeValue
Feb 15, 2022KTRA↑ Buy$26K
Jul 2, 2018HRTX↓ Sell$1.1M
May 10, 2016CBMX↑ Buy$16K
Dec 16, 2014MBVX↑ Buy$24K
Apr 1, 2013ARNA↓ Sell$585K
Oct 1, 2012ARNA↓ Sell$416K
Jul 5, 2012ARNA↓ Sell$110K
Sep 2, 2008ARNA↓ Sell$62K
Jul 31, 2006ARNA↓ Sell$78K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About Robert E. Hoffman's insider trades

Robert E. Hoffman is President, CEO and Interim CFO at Kintara Therapeutics (KTRA). Since Jul 31, 2006, Robert has reported 3 open-market purchases worth $66K and 6 sales worth $2.4M on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include grants and awards (53 filings), other transactions (9 filings), option exercises (6 filings), gifts (3 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every KTRA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.